Abstract
Secukinumab is a human immunoglobulin G1/κ monoclonal antibody targeting interleukin-17A. In clinical trials, 77-81% of the secukinumab patients achieved a PASI75 response in 12 weeks. As well as in chronic plaque psoriasis, secukinumab has also been found effective and safe as monotherapy in nail and hairy skin psoriasis and psoriatic arthritis. Secukinumab should be used with caution in patients or their first-degree relatives who have inflammatory bowel disease. It has a safe side effect profile in terms of latent tuberculosis activation.
Author supplied keywords
Cite
CITATION STYLE
Atakan, N. (2022). Secukinumab. Turkderm Turkish Archives of Dermatology and Venereology, 56, 52–54. https://doi.org/10.4274/turkderm.galenos.2022.37929
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
